application): The goal of this project is to validate a new method for drug-lead discovery that relies on cascaded multi-step selection of small chemical groups to construct larger molecules having high affinity for a protein target. This method increases efficiency over combinatorial chemistry in executing the selection before, rather than after, chemical synthesis. This technology will be developed using thymidylate synthase, a validated target for anti-cancer and anti-proliferative agents.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43CA085141-02
Application #
6345558
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (01))
Program Officer
Lees, Robert G
Project Start
1999-07-01
Project End
2001-02-28
Budget Start
2000-09-01
Budget End
2001-02-28
Support Year
2
Fiscal Year
2000
Total Cost
$109,200
Indirect Cost
Name
Sunesis Pharmaceuticals, Inc.
Department
Type
DUNS #
City
South San Francisco
State
CA
Country
United States
Zip Code
94080
Erlanson, D A; Braisted, A C; Raphael, D R et al. (2000) Site-directed ligand discovery. Proc Natl Acad Sci U S A 97:9367-72